Acumen appoints Dr. Derrell Porter to board effective Jan. 4, 2023

Acumen Pharmaceuticals, Inc.

Dr. Porter appointed as Class II independent director; named to Nominating and Governance Committee.
He receives 50,000-share stock option with 10-yr term, vesting monthly over 3 years.
Annual retainer of $35,000 for board service and $4,000 for committee service.
Dr. Porter is Founder/CEO of Cellevolve; brings drug development and commercialization expertise.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Derrell Porter

director

ABOS · Acumen Pharmaceuticals, Inc.

Effective: 2023-01-04
Filed: January 4, 2023, 6:59 PM ET

On January 3, 2023, the Board of Directors (the “ Board ”) of Acumen Pharmaceuticals, Inc. (the “ Company ”) approved the appointment of Dr. Derrell Porter to serve as a director on the Board, effective January 4, 2023 (the “ Effective Date ”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Derrell Porter was appointed as director at Acumen Pharmaceuticals, Inc..

Action: appointed
Role: director

Exact text from the filing

On January 3, 2023, the Board of Directors (the “ Board ”) of Acumen Pharmaceuticals, Inc. (the “ Company ”) approved the appointment of Dr. Derrell Porter to serve as a director on the Board, effective January 4, 2023 (the “ Effective Date ”).

View on SEC.gov

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-001236

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.